02 Apr , 2026 By : Debdeep Gupta
Pharma shares declined up to 4 percent in Thursday’s trade after reports that the administration of US president Donald Trump may announce tariffs on drugmakers that have not entered into agreements to ensure lower prices in the United States.
Shares of Biocon, Sun Pharmaceutical Industries and Divi's Laboratories were among the major losers.
The Nifty Pharma index extended losses for the fourth consecutive session, falling more than 5 percent, with all its 20 constituents trading in the red.
In intraday trade, Biocon declined up to 4 percent. Ipca Laboratories fell 3.83 percent, while Torrent Pharmaceuticals dropped 3.67 percent.
Shares of Sun Pharmaceutical Industries were down over 3 percent, while Divi's Laboratories fell more than 2 percent.
According to reports, the US has been considering a 100 percent tariff on imported branded and patented medicines. Trump has for months indicated tariffs on pharmaceutical companies, ranging from 100 percent to 200 percent, aimed at pushing manufacturing back to the US and reducing drug prices.
Several global drugmakers, including Pfizer Inc. and Eli Lilly and Company, have entered into agreements with the White House, securing a three-year relief from such levies.
The proposed tariffs are linked to an investigation under Section 232 of the Trade Expansion Act. Companies without agreements or ongoing negotiations with the administration may face tariffs of up to 100 percent, according to sources.
The pharmaceutical sector had earlier been spared from global levies imposed in 2025 after the administration reached individual agreements with more than a dozen companies.
0 Comment